• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For a lot of people suffering from depression, traditional therapy and medications are not effective. A customized treatment could be the solution.

Cue is a digital intervention platform that transforms passively acquired smartphone sensor data into personalized micro-interventions designed to improve mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to understand their feature predictors and reveal distinct characteristics that can be used to predict changes in mood over time.

Predictors of Mood

Depression is among the leading causes of mental illness.1 Yet, only half of those suffering from the disorder receive treatment1. To improve outcomes, doctors must be able to identify and treat patients with the highest chance of responding to certain treatments.

Personalized depression treatment can help. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will benefit most from specific treatments. They are using mobile phone sensors and a voice assistant incorporating artificial intelligence and other digital tools. Two grants totaling more than $10 million will be used to identify the biological and behavioral indicators of response.

So far, the majority of research on predictors for depression treatment effectiveness has been focused on the sociodemographic and clinical aspects. These include demographics such as gender, age, and education, as well as clinical characteristics such as symptom severity and comorbidities as well as biological markers.

While many of these variables can be predicted from information available in medical records, only a few studies have employed longitudinal data to study predictors of mood in individuals. They have not taken into account the fact that mood can vary significantly between individuals. Therefore, it is critical to develop methods that permit the identification of the individual differences in mood predictors and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to identify patterns of behaviour and emotions that are unique to each person.

In addition to these modalities, the team created a machine learning algorithm that models the dynamic predictors of each person's depressed mood. The algorithm blends the individual differences to produce an individual "digital genotype" for each participant.

This digital phenotype has been linked to CAT DI scores which is a psychometrically validated symptom severity scale. However, the correlation was weak (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 1003) and varied widely among individuals.

Predictors of Symptoms

Depression is a leading cause of disability in the world, but it is often misdiagnosed and untreated2. Depression disorders are rarely treated due to the stigma attached to them, as well as the lack of effective interventions.

To assist in individualized treatment, it is essential to determine the predictors of symptoms. However, current prediction methods depend on the clinical interview which is unreliable and only detects a limited variety of characteristics associated with depression.2

Machine learning can enhance the accuracy of diagnosis and treatment for depression by combining continuous digital behavior patterns gathered from sensors on smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes allow continuous, high-resolution measurements and capture a variety of distinct behaviors and patterns that are difficult to capture with interviews.

The study comprised University of California Los Angeles students with mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29 developed as part of the UCLA Depression Grand Challenge. Participants were referred to online support or to clinical treatment according to the severity of their depression. Participants who scored a high on the CAT-DI of 35 65 were allocated online support via an online peer coach, whereas those with a score of 75 patients were referred for psychotherapy in person.

At the beginning of the interview, participants were asked the answers to a series of questions concerning their personal demographics and psychosocial features. The questions asked included age, sex and education, marital status, financial status, whether they were divorced or not, their current suicidal ideas, intent or attempts, as well as the frequency with which they consumed alcohol. Participants also scored their level of depression severity on a scale ranging from 0-100 using the CAT-DI. CAT-DI assessments were conducted every other week for participants that received online support, and every week for those who received in-person support.

Predictors of Treatment Reaction

The development of a personalized depression treatment is currently a major research area and many studies aim at identifying predictors that allow clinicians to identify the most effective drugs for each individual. Pharmacogenetics in particular uncovers genetic variations that affect how the body's metabolism reacts to drugs. This lets doctors select the medication that are most likely to work for each patient, while minimizing the time and effort needed for trials and errors, while eliminating any adverse effects.

Another promising approach is to create predictive models that incorporate clinical data and neural imaging data. These models can be used to determine the most appropriate combination of variables that are predictors of a specific outcome, such as whether or not a drug will improve mood and symptoms. These models can be used to determine the response of a patient to a treatment they are currently receiving which allows doctors to maximize the effectiveness of their current therapy.

A new generation uses machine learning techniques like supervised and classification algorithms, regularized logistic regression and tree-based methods to combine the effects from multiple variables and improve predictive accuracy. These models have been shown to be useful in predicting the outcome of treatment, such as response to antidepressants. These approaches are gaining popularity in psychiatry, and it is likely that they will become the standard for the future of clinical practice.

Research into depression's underlying mechanisms continues, in addition to ML-based predictive models. Recent findings suggest that the disorder is connected with neurodegeneration in particular circuits. This suggests that individual depression and anxiety treatment near me treatment will be built around targeted treatments that target these neural circuits to restore normal function.

Internet-based interventions are a way to accomplish this. They can offer more customized and personalized experience for patients. A study showed that an internet-based program helped improve symptoms and led to a better quality of life for MDD patients. Furthermore, a randomized controlled study of a customized treatment for depression demonstrated sustained improvement and reduced side effects in a significant number of participants.

Predictors of adverse effects

In the treatment of depression, the biggest challenge is predicting and identifying which antidepressant medications will have minimal or zero adverse negative effects. Many patients experience a trial-and-error method, involving various medications being prescribed before settling on one that is effective treatments for depression and tolerable. Pharmacogenetics provides an exciting new method for an effective and precise method of selecting antidepressant therapies.

Many predictors can be used to determine which antidepressant is best to prescribe, including genetic variations, phenotypes of patients (e.g. sexual orientation, gender or ethnicity) and comorbidities. However it is difficult to determine the most reliable and valid factors that can predict the effectiveness of a particular treatment is likely to require randomized controlled trials with considerably larger samples than those normally enrolled in clinical trials. This is because it could be more difficult to identify moderators or interactions in trials that only include one episode per person rather than multiple episodes over time.

Furthermore the prediction of a patient's reaction to a particular medication is likely to require information on symptoms and comorbidities and the patient's prior subjective experiences with the effectiveness and tolerability of the medication. Currently, only a few easily measurable sociodemographic variables as well as clinical variables seem to be reliably related to response to MDD. These include age, gender and race/ethnicity, SES, BMI and the presence of alexithymia.

Many issues remain to be resolved in the application of pharmacogenetics to treat depression. first line treatment for depression and anxiety [https://telegra.ph/are-depression-Treatment-programs-Just-as-Important-as-everyone-says-08-09], a clear understanding of the underlying genetic mechanisms is essential as well as an understanding of what is a reliable indicator of treatment response. Ethics such as privacy and the responsible use of genetic information are also important to consider. The use of pharmacogenetics may be able to, over the long term reduce stigma associated with treatments for mental illness and improve the quality of treatment. Like any other psychiatric treatment it is essential to give careful consideration and implement the plan. At present, the most effective course of action is to provide patients with an array of effective medications for depression and encourage them to talk openly with their doctors about their experiences and concerns.